Vildagliptin: peripheral oedema and nasopharyngitis Interactions Clinically significant drug interactions are described as follows: *Sitagliptin is metabolised primarily by CYP3A4, in severe renal impairment metabolism plays a more significant role in sitagliptin elimination, therefore potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) may increase sitagliptin plasma levels in severe renal impairment The blood glucose-lowering effects of DPP-4 inhibitors may also be enhanced or inhibited by other substances: References DPP-4 inhibitors | Prescribing information | Diabetes type 2 | CKS | NICE Sitagliptin 100 mg Film-coated Tablets Summary of Product Characteristics (SmPC) (emc) Onglyza 2.5mg film-coated tablets Summary of Product Characteristics (SmPC) (emc) Trajenta 5 mg film-coated tablets Summary of Product Characteristics (SmPC) (emc) Alogliptin 12.5 mg film-coated tablets Summary of Product Characteristics (SmPC) (emc)
As both an antioxidant and natural detoxifier, it also constitutes a useful ingredient for countering the effects of aging
The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects
It didnt have to be this way
